Johnson & Johnson's nipocalimab could become the first approved treatment for a blood disorder that can lead to the death of a foetus or newborn, if positive results i
Biogen's efforts to replenish its multiple sclerosis pipeline have suffered a setback, after the FDA placed a clinical hold on a drug candidate it licensed from China's InnoCare last year f
Merck & Co has made another move towards diversifying its pipeline and reducing its reliance on blockbuster cancer drug Keytruda, pledging $525 million to an alliance with Synthekine in
Almirall has licensed an interleukin-2 (IL-2) drug from China's Simcere Pharma, joining the ranks of companies looking at blocking the cytokine as a way to treat autoimmune diseases.
Alphabet subsidiary and precision health company Verily recently announced a breakthrough in its AI drug discovery GPCR research collaboration with Sosei Heptares.
As the ASCO congress drew to a close, Johnson & Johnson filed for FDA approval of its BCMA-targeting CAR-T therapy Carvykti for use earlier in the treatment pathway fo
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas
